Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,392,610
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
79,306,949
-
Shares change
-
+12,998,954
-
Total reported value, excl. options
-
$3,007,317,130
-
Value change
-
+$505,416,563
-
Put/Call ratio
-
974%
-
Number of buys
-
109
-
Number of sells
-
78
-
Price
-
$37.92
Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q3 2025
As of 30 Sep 2025 Mineralys Therapeutics, Inc. - Common Stock (MLYS) had 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 79,306,949 shares of stock of the company.
Largest 10 holders included Catalys Pacific, LLC, RA CAPITAL MANAGEMENT, L.P., SAMSARA BIOCAPITAL, LLC, BlackRock, Inc., VANGUARD GROUP INC, Caligan Partners LP, Capital International Investors, SUVRETTA CAPITAL MANAGEMENT, LLC, SR One Capital Management, LP, and FMR LLC.
This table shows 191 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.